 Timothy Ashby
Concepts (188)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Multiple Myeloma | 34 | 2024 | 3049 | 2.560 |
Why?
| | High-Throughput Nucleotide Sequencing | 7 | 2022 | 206 | 1.230 |
Why?
| | Genomics | 10 | 2023 | 313 | 0.910 |
Why?
| | Software | 4 | 2021 | 297 | 0.890 |
Why?
| | Mutation | 14 | 2022 | 1504 | 0.860 |
Why?
| | Clonal Evolution | 4 | 2020 | 60 | 0.620 |
Why?
| | Plasma Cells | 6 | 2023 | 239 | 0.600 |
Why?
| | Computational Biology | 4 | 2020 | 231 | 0.580 |
Why?
| | Algorithms | 4 | 2020 | 697 | 0.520 |
Why?
| | Neoplasm Recurrence, Local | 5 | 2024 | 645 | 0.500 |
Why?
| | Translocation, Genetic | 7 | 2022 | 287 | 0.420 |
Why?
| | Monoclonal Gammopathy of Undetermined Significance | 2 | 2023 | 108 | 0.420 |
Why?
| | Neoplasms | 2 | 2020 | 1321 | 0.420 |
Why?
| | Hematopoietic Stem Cell Transplantation | 3 | 2024 | 583 | 0.410 |
Why?
| | Osteolysis | 2 | 2022 | 87 | 0.410 |
Why?
| | Models, Molecular | 1 | 2013 | 423 | 0.400 |
Why?
| | Chromosome Aberrations | 3 | 2023 | 316 | 0.380 |
Why?
| | Evolution, Molecular | 2 | 2021 | 103 | 0.380 |
Why?
| | Genome, Human | 3 | 2021 | 131 | 0.380 |
Why?
| | Gene Expression Profiling | 9 | 2023 | 1141 | 0.370 |
Why?
| | Humans | 42 | 2024 | 54304 | 0.370 |
Why?
| | Proteins | 1 | 2013 | 376 | 0.360 |
Why?
| | Prognosis | 11 | 2024 | 2126 | 0.350 |
Why?
| | Epigenomics | 2 | 2021 | 67 | 0.330 |
Why?
| | Bone Marrow | 3 | 2020 | 414 | 0.330 |
Why?
| | Gene Expression Regulation, Neoplastic | 4 | 2021 | 868 | 0.320 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 4 | 2020 | 1060 | 0.290 |
Why?
| | Gene Rearrangement | 2 | 2023 | 76 | 0.260 |
Why?
| | Oncogenes | 3 | 2021 | 63 | 0.260 |
Why?
| | Disease Progression | 7 | 2023 | 915 | 0.260 |
Why?
| | Burkitt Lymphoma | 1 | 2023 | 29 | 0.220 |
Why?
| | Tumor Microenvironment | 2 | 2023 | 210 | 0.220 |
Why?
| | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2023 | 13 | 0.220 |
Why?
| | Gene Dosage | 2 | 2020 | 92 | 0.220 |
Why?
| | Epigenesis, Genetic | 3 | 2023 | 399 | 0.220 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2023 | 176 | 0.210 |
Why?
| | Proto-Oncogene Proteins B-raf | 2 | 2020 | 92 | 0.210 |
Why?
| | Cell Communication | 1 | 2022 | 72 | 0.210 |
Why?
| | Neoplasm Proteins | 2 | 2021 | 360 | 0.200 |
Why?
| | Telomere Homeostasis | 1 | 2021 | 11 | 0.200 |
Why?
| | Ubiquitination | 1 | 2021 | 47 | 0.200 |
Why?
| | Polycomb Repressive Complex 2 | 1 | 2021 | 50 | 0.200 |
Why?
| | Chromosome Deletion | 2 | 2023 | 150 | 0.200 |
Why?
| | Loss of Heterozygosity | 2 | 2018 | 97 | 0.190 |
Why?
| | Lymphoma, B-Cell | 1 | 2021 | 62 | 0.190 |
Why?
| | Positron-Emission Tomography | 2 | 2022 | 323 | 0.190 |
Why?
| | Genes, Tumor Suppressor | 2 | 2021 | 85 | 0.190 |
Why?
| | B-Lymphocytes | 1 | 2021 | 176 | 0.190 |
Why?
| | Sequence Analysis, DNA | 2 | 2018 | 274 | 0.180 |
Why?
| | Lymphoma, Follicular | 1 | 2020 | 30 | 0.180 |
Why?
| | Exosome Multienzyme Ribonuclease Complex | 1 | 2020 | 14 | 0.180 |
Why?
| | Leukemia, Plasma Cell | 1 | 2020 | 34 | 0.180 |
Why?
| | Cell Cycle | 1 | 2021 | 275 | 0.180 |
Why?
| | Cell Cycle Proteins | 1 | 2021 | 198 | 0.180 |
Why?
| | Bone Resorption | 1 | 2022 | 328 | 0.180 |
Why?
| | Gene Regulatory Networks | 1 | 2020 | 124 | 0.180 |
Why?
| | Osteocytes | 1 | 2022 | 219 | 0.170 |
Why?
| | Genes, myc | 1 | 2019 | 47 | 0.170 |
Why?
| | Tumor Suppressor Protein p53 | 2 | 2017 | 251 | 0.160 |
Why?
| | Transplantation, Autologous | 4 | 2024 | 485 | 0.160 |
Why?
| | Mutagenesis | 1 | 2018 | 77 | 0.160 |
Why?
| | Diffusion Magnetic Resonance Imaging | 1 | 2018 | 128 | 0.160 |
Why?
| | Homologous Recombination | 1 | 2018 | 43 | 0.160 |
Why?
| | Neoplasm, Residual | 1 | 2018 | 167 | 0.160 |
Why?
| | Genome | 1 | 2018 | 74 | 0.160 |
Why?
| | Chromosomes, Human, Pair 17 | 1 | 2017 | 43 | 0.150 |
Why?
| | Survival Rate | 4 | 2021 | 954 | 0.150 |
Why?
| | Transcriptome | 2 | 2020 | 346 | 0.150 |
Why?
| | DNA Repair | 1 | 2018 | 203 | 0.140 |
Why?
| | Flow Cytometry | 1 | 2018 | 547 | 0.140 |
Why?
| | DNA Copy Number Variations | 3 | 2022 | 114 | 0.130 |
Why?
| | Female | 10 | 2021 | 28457 | 0.130 |
Why?
| | Remission Induction | 3 | 2021 | 222 | 0.130 |
Why?
| | Genes, Neoplasm | 1 | 2015 | 36 | 0.130 |
Why?
| | Aged | 8 | 2021 | 10054 | 0.130 |
Why?
| | Pattern Recognition, Automated | 1 | 2015 | 45 | 0.130 |
Why?
| | Aged, 80 and over | 5 | 2021 | 3430 | 0.130 |
Why?
| | Cluster Analysis | 1 | 2015 | 244 | 0.120 |
Why?
| | Middle Aged | 8 | 2021 | 13076 | 0.120 |
Why?
| | Follow-Up Studies | 4 | 2021 | 2389 | 0.120 |
Why?
| | Databases, Protein | 1 | 2013 | 29 | 0.110 |
Why?
| | Protein Structure, Secondary | 1 | 2013 | 99 | 0.110 |
Why?
| | Sequence Alignment | 1 | 2013 | 146 | 0.110 |
Why?
| | Mice | 5 | 2023 | 6428 | 0.110 |
Why?
| | Male | 10 | 2021 | 27335 | 0.110 |
Why?
| | Chromatin | 2 | 2023 | 156 | 0.100 |
Why?
| | Amino Acid Sequence | 1 | 2013 | 766 | 0.100 |
Why?
| | T-Lymphocytes | 2 | 2024 | 374 | 0.100 |
Why?
| | Mutation Rate | 2 | 2021 | 40 | 0.100 |
Why?
| | Adenocarcinoma | 1 | 2015 | 428 | 0.100 |
Why?
| | Breast Neoplasms | 1 | 2020 | 1248 | 0.090 |
Why?
| | In Situ Hybridization, Fluorescence | 2 | 2023 | 278 | 0.090 |
Why?
| | Tumor Burden | 2 | 2020 | 141 | 0.090 |
Why?
| | Alleles | 2 | 2021 | 277 | 0.090 |
Why?
| | Clone Cells | 2 | 2021 | 89 | 0.090 |
Why?
| | Adult | 6 | 2021 | 14189 | 0.090 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 2 | 2021 | 70 | 0.090 |
Why?
| | DNA, Neoplasm | 2 | 2020 | 171 | 0.080 |
Why?
| | Lung Neoplasms | 1 | 2015 | 643 | 0.080 |
Why?
| | Histones | 2 | 2021 | 335 | 0.080 |
Why?
| | DNA Mutational Analysis | 2 | 2020 | 217 | 0.080 |
Why?
| | Treatment Outcome | 4 | 2020 | 5609 | 0.080 |
Why?
| | Animals | 5 | 2023 | 14402 | 0.080 |
Why?
| | DNA Methylation | 2 | 2023 | 575 | 0.080 |
Why?
| | Recurrence | 2 | 2021 | 692 | 0.070 |
Why?
| | Genomic Instability | 2 | 2018 | 95 | 0.070 |
Why?
| | Risk Factors | 3 | 2021 | 3934 | 0.070 |
Why?
| | Cell Proliferation | 2 | 2021 | 1097 | 0.060 |
Why?
| | Signal Transduction | 2 | 2022 | 1751 | 0.060 |
Why?
| | Ferritins | 1 | 2024 | 31 | 0.060 |
Why?
| | Internet | 2 | 2018 | 275 | 0.060 |
Why?
| | Myeloid Progenitor Cells | 1 | 2023 | 19 | 0.060 |
Why?
| | B-Cell Maturation Antigen | 1 | 2024 | 72 | 0.060 |
Why?
| | Integrin beta Chains | 1 | 2023 | 14 | 0.060 |
Why?
| | Antibodies | 1 | 2024 | 178 | 0.060 |
Why?
| | Integrins | 1 | 2023 | 36 | 0.060 |
Why?
| | Oxidative Phosphorylation | 1 | 2023 | 57 | 0.060 |
Why?
| | Cytogenetic Analysis | 1 | 2023 | 90 | 0.060 |
Why?
| | TNF Receptor-Associated Factor 3 | 1 | 2022 | 14 | 0.060 |
Why?
| | Cystatin M | 1 | 2022 | 21 | 0.060 |
Why?
| | Chromosomes, Human, Pair 1 | 1 | 2023 | 113 | 0.050 |
Why?
| | Immunoglobulins | 1 | 2023 | 89 | 0.050 |
Why?
| | Forkhead Transcription Factors | 1 | 2023 | 118 | 0.050 |
Why?
| | Syndecan-1 | 1 | 2021 | 82 | 0.050 |
Why?
| | Phylogeny | 1 | 2022 | 269 | 0.050 |
Why?
| | Spliceosomes | 1 | 2021 | 10 | 0.050 |
Why?
| | RANK Ligand | 1 | 2022 | 183 | 0.050 |
Why?
| | Transcriptional Activation | 1 | 2021 | 134 | 0.050 |
Why?
| | RNA Splicing | 1 | 2021 | 38 | 0.050 |
Why?
| | Alternative Splicing | 1 | 2021 | 64 | 0.050 |
Why?
| | Cyclin D2 | 1 | 2020 | 20 | 0.050 |
Why?
| | Spatio-Temporal Analysis | 1 | 2020 | 10 | 0.050 |
Why?
| | Aneuploidy | 1 | 2020 | 23 | 0.050 |
Why?
| | Proto-Oncogene Proteins c-maf | 1 | 2020 | 20 | 0.050 |
Why?
| | Chromosomes, Human, Pair 4 | 1 | 2020 | 30 | 0.050 |
Why?
| | Gene Expression Regulation, Leukemic | 1 | 2020 | 36 | 0.050 |
Why?
| | Histone Code | 1 | 2020 | 32 | 0.050 |
Why?
| | Cyclin D1 | 1 | 2020 | 60 | 0.050 |
Why?
| | Chromosomes, Human, Pair 11 | 1 | 2020 | 54 | 0.050 |
Why?
| | ras Proteins | 1 | 2020 | 70 | 0.050 |
Why?
| | Phosphoproteins | 1 | 2021 | 116 | 0.050 |
Why?
| | Chromosomes, Human, Pair 14 | 1 | 2020 | 76 | 0.050 |
Why?
| | Ecosystem | 1 | 2021 | 90 | 0.050 |
Why?
| | Single-Cell Analysis | 1 | 2020 | 56 | 0.050 |
Why?
| | Protein Disulfide-Isomerases | 1 | 2019 | 15 | 0.040 |
Why?
| | Genes, Immunoglobulin Heavy Chain | 1 | 2019 | 14 | 0.040 |
Why?
| | Melphalan | 1 | 2020 | 184 | 0.040 |
Why?
| | Cell Differentiation | 1 | 2022 | 720 | 0.040 |
Why?
| | Neoplasm Invasiveness | 1 | 2020 | 294 | 0.040 |
Why?
| | Mice, Transgenic | 1 | 2021 | 658 | 0.040 |
Why?
| | Osteoclasts | 1 | 2022 | 469 | 0.040 |
Why?
| | Genetic Variation | 1 | 2020 | 253 | 0.040 |
Why?
| | DNA | 1 | 2023 | 581 | 0.040 |
Why?
| | Combined Modality Therapy | 1 | 2021 | 693 | 0.040 |
Why?
| | Osteogenesis | 1 | 2022 | 377 | 0.040 |
Why?
| | Multivariate Analysis | 1 | 2021 | 643 | 0.040 |
Why?
| | Maintenance Chemotherapy | 1 | 2019 | 48 | 0.040 |
Why?
| | Cell Line, Tumor | 1 | 2023 | 1551 | 0.040 |
Why?
| | Cell Survival | 1 | 2020 | 657 | 0.040 |
Why?
| | 25-Hydroxyvitamin D3 1-alpha-Hydroxylase | 1 | 2017 | 9 | 0.040 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p18 | 1 | 2017 | 28 | 0.040 |
Why?
| | Promoter Regions, Genetic | 1 | 2020 | 520 | 0.040 |
Why?
| | Genome-Wide Association Study | 1 | 2018 | 190 | 0.040 |
Why?
| | STAT3 Transcription Factor | 1 | 2017 | 88 | 0.040 |
Why?
| | Fibroblast Growth Factors | 1 | 2017 | 60 | 0.040 |
Why?
| | Information Dissemination | 1 | 2018 | 104 | 0.040 |
Why?
| | Reproducibility of Results | 1 | 2021 | 1294 | 0.040 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2017 | 170 | 0.040 |
Why?
| | Genes, ras | 1 | 2016 | 48 | 0.040 |
Why?
| | Proportional Hazards Models | 1 | 2018 | 430 | 0.040 |
Why?
| | Thalidomide | 1 | 2019 | 398 | 0.040 |
Why?
| | Genes, p53 | 1 | 2016 | 60 | 0.040 |
Why?
| | Prospective Studies | 1 | 2023 | 2604 | 0.040 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2020 | 1476 | 0.040 |
Why?
| | Kaplan-Meier Estimate | 1 | 2018 | 514 | 0.040 |
Why?
| | Cohort Studies | 1 | 2020 | 1547 | 0.030 |
Why?
| | Models, Genetic | 1 | 2016 | 208 | 0.030 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2016 | 153 | 0.030 |
Why?
| | Stem Cell Transplantation | 1 | 2016 | 201 | 0.030 |
Why?
| | Survival Analysis | 1 | 2017 | 736 | 0.030 |
Why?
| | Dogs | 1 | 2015 | 216 | 0.030 |
Why?
| | Databases, Genetic | 1 | 2015 | 101 | 0.030 |
Why?
| | Sequence Analysis, RNA | 1 | 2015 | 107 | 0.030 |
Why?
| | Genetic Testing | 1 | 2015 | 135 | 0.030 |
Why?
| | Longitudinal Studies | 1 | 2016 | 742 | 0.030 |
Why?
| | Time Factors | 1 | 2021 | 3207 | 0.030 |
Why?
| | Retrospective Studies | 1 | 2024 | 6462 | 0.030 |
Why?
| | Child | 1 | 2023 | 7372 | 0.020 |
Why?
|
|
Ashby's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|